[SHINSA]The information of New Drug Review with Electronic Data updated
Safety Classified by Officially
In recent drug development, the use of data-based quantitative information such as those using modeling and simulation (M&S) methods has been proactively promoted in decision-making process.
Under such circumstances, PMDA recognizes the need for accumulating electronic study data, analyzing the data by advanced methods, and making use of the data in the process of its reviews and consultations. The use of such accumulated data is expected to reduce the workload of regulatory submission for sponsors, improve PMDA's evidence-based reviews and consultations, and lead to development of new guidelines, which will eventually result in the rise of the success rate of drug development.
This webpage provides related information about new drug review with electronic data.
Revision of Notification on Handling of Submission of Electronic Study Data for New Drug Applications (PSB/PED Notification No. 0408-3, by the Director of Pharmaceutical Evaluation Division, Pharmaceutical Safety Bureau, Ministry of Health, Labour and Welfare, dated April 8, 2024)
Question and Answer Guide Regarding "Notification on Handling of Submission of Electronic Study Data for New Drug Applications” (Administrative Notice of the Pharmaceutical Evaluation Division, Pharmaceutical Safety Bureau, Ministry of Health, Labour and Welfare, dated April 8, 2024)
New Drug Applications Using the Gateway System (PSEHB/PED Notification No. 0401-7, by the Director of the Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare, dated April 1, 2022)
Revision of Technical Conformance Guide on Electronic Study Data Submissions (PMDA/CPE Notification No. 1345 and PMDA/CRS Notification No. 21, by the Director of Center for Product Evaluation and the Director of Center for RS, Pharmaceuticals and Medical Devices Agency, dated April 8, 2024)
FAQs on Electronic Study Data Submission
This is an extract. The publication continues at the source.
Source: Pharmaceuticals and Medical Devices Agency (Japan) website. Licence
Read the original at the source: https://www.pmda.go.jp/english/review-services/reviews/0002.html
Officially imported this from Pharmaceuticals and Medical Devices Agency (Japan)’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- Pharmaceuticals and Medical Devices Agency (Japan) — imported from official source
- Official source
- https://www.pmda.go.jp/rss_008.xml RSS
- Imported
- November 09, 2026 01:32
- Versions
- 1 recorded
- Identity
-
https://www.pmda.go.jp/english/review-services/reviews/0002.html